Compound Notes 4 min read
Epitalon: A Plain-English Guide to the Russian Pineal Peptide
A patient explainer on Epitalon, where the research came from, what the proposed mechanism is, and how to think about a compound whose evidence base is real but more limited than the longevity-supplement marketing suggests.
Last reviewed: May 2026
If you have spent any time reading about longevity peptides, you have probably hit Epitalon. The descriptions tend to fall in two categories. One is a paragraph of mystical-sounding claims about telomere extension and Russian secret science. The other is a dismissive line about how the research is unreplicable and the compound is mostly hype. Both miss what is actually interesting about Epitalon, which sits between the two.
Here is the patient version.
What Epitalon is, structurally
Epitalon is a four-amino-acid peptide. The sequence is alanine-glutamic acid-aspartic acid-glycine, sometimes written Ala-Glu-Asp-Gly or just AEDG. It is one of the smaller research peptides in the catalogue. Small enough that it survives intramuscular and subcutaneous injection well. Small enough that some forms of oral and intranasal delivery have been explored, though injection remains the standard research-protocol route.
The compound is synthetic, but the inspiration came from a natural source. The original work in Vladimir Khavinson’s lab at the St. Petersburg Institute of Bioregulation and Gerontology started with extracts from the bovine pineal gland. The pineal is a small endocrine organ that secretes melatonin and a number of less-famous regulatory peptides. Khavinson’s group spent decades isolating those peptides, characterising the amino-acid sequences, and synthesising the active fragments. Epitalon is the synthetic version of one of those fragments.
The proposed mechanism
The mechanism story has two parts. The first is straightforward. Epitalon appears to influence gene expression by binding short stretches of DNA in a sequence-specific way. This is a documented function of small peptides generally, and the molecular biology is plausible. Different short peptides bind different DNA sequences and modulate the genes near those sites.
The second part is the one that gets quoted in supplement marketing. Khavinson’s group reported that Epitalon increased telomerase activity in cell culture and partially extended telomeres in some animal models. Telomerase is the enzyme that adds DNA repeats back to chromosome ends, the same enzyme covered in our telomere science piece. If Epitalon really does activate telomerase in human tissues at typical research doses, that would be biologically interesting. The evidence for that specific effect, in humans, at protocol doses, is more limited than the marketing implies.
Why the evidence base is the way it is
Most of the published Epitalon research came from one institutional ecosystem in St. Petersburg. The studies are real and they are published in legitimate journals. They have not been independently replicated at the scale that supports compounds like NAD+ precursors or BPC-157. This is not the same as the research being wrong. It is closer to saying that one research group has done most of the work, the work is consistent within itself, and the broader field has not stress-tested the findings the way it would for a compound with bigger commercial stakes.
If you find this frustrating, you are not alone. The peptide-research field has a number of compounds in this position. The honest reader’s posture is somewhere between cautious optimism and reserved skepticism. The compound has plausible mechanism. The replication picture is incomplete. Treating the available evidence as definitive proof would be overclaiming. Dismissing the compound entirely would be over-skeptical.
What the typical research protocol looks like
Standard Epitalon protocol patterns from the published work run 5 to 10 mg per administration, daily for 10 to 20 days, in courses repeated once or twice per year. The compound is usually injected subcutaneously. Reconstitution is straightforward and follows the same pattern as any lyophilised peptide. The Dosage Calculator handles the syringe-units conversion.
The dose pattern is unusual compared to most peptide protocols, which tend to run continuously for weeks. Epitalon courses are short and infrequent. This reflects the compound’s hypothesised mechanism: it is supposed to nudge gene expression and then let the cell do the rest of the work. Whether that mechanism description is accurate is part of what the replication picture has not fully resolved.
What pairs with Epitalon in a longevity stack
For researchers building a longevity-context protocol around the cellular-aging story, Epitalon often sits alongside compounds that address other hallmarks of aging:
- NAD+ for the cofactor pathway and the sirtuin signalling that interacts with cellular aging
- MOTS-c for the mitochondrial-maintenance side, covered in our mitochondrial piece
- Nightfall for the sleep-architecture support that many longevity protocols depend on
The Protocol Builder Longevity goal includes Epitalon in the curated stack with realistic framing about the evidence picture.
The honest takeaway
Epitalon is a peptide with plausible mechanism, a real but narrow research base, and reasonable inclusion in a longevity-context protocol if you hold realistic expectations. It is not the hero of any sensible stack. It is not snake oil either. It is a compound where the right posture is curiosity rather than certainty.
If a product page promises that Epitalon will reverse aging or extend your life by ten years, that page is not telling you the truth. If a forum thread tells you Epitalon is a complete fraud, that thread is also overshooting in the opposite direction. The compound deserves the middle treatment, which is the one the research base supports.